ITCI
$26.10
Intra-Cellular Ther
$.35
1.36%
ITCI
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.96)
Revenue:  $6.50 Mil
Tuesday
Nov 3
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ITCI reports earnings?
Beat
Meet
Miss

Where is ITCI's stock price going from here?
Up
Flat
Down
Stock chart of ITCI
Analysts
Summary of analysts' recommendations for ITCI
Score
Grade
Pivots
Resistance
$27.18
$26.69
$26.39

$25.90

Support
$25.60
$25.11
$24.81
Tweet
Growth
Description
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalZoetisBristol-Myers SquibbJohnson & JohnsonMerck & Co.PfizerUltragenyx Pharmaceutical